Effects of baicalin in CD4 + CD29 + T cell subsets of ulcerative colitis patients

Table 1 Treatments designed for the in-vitro culture of peripheral blood mononuclear cells

No.	1	2	3	4	5	6
Treatment	Cell (PBMCs of UC group)	DMSO	5 μmol/L baicalin	10 μmol/L baicalin	20 μmol/L baicalin	40 μmol/L baicalin

Table 2 Polymerase chain reaction primers used in this study

Gene name	Primer
GATA3	Forward	AGTTGGCCTAAGGTGGTTG
	Reverse	CACGCTGGTAGCTCATACAC
FOXP3	Forward	CAGGATCTGAGGTCCCAACA
	Reverse	TTTGGCAAGGCAGTGTGTGT
T-bet	Forward	CTGCATATCGTTGAGGTGAA
	Reverse	GTAGGCAGTCACGGCAATGA
RORC	Forward	CAAGACTCATCGCCAAAGCA
	Reverse	CAGTGCTGAAGAGCTCCTTG
18S	Forward	CCTGGATACCGCAGCTAGGA
	Reverse	GCGGCGCAATACGAATGCCCC

Table 3 Percentage (%, mean ± SD) of CD4⁺CD29⁺ cells in peripheral blood of participants of each group

Groups	CD4+ cells	CD4+CD29+ cells
UC group	41.56% ± 3.6%a	8.33% ± 1.25%a
D-IBS group	20.12% ± 3.4%	2.42% ± 1.12%
Control group	19.37% ± 4.1%	1.91% ± 2.35%

^aP < 0.05 vs control group. Datas presented as mean ± SD. UC: Ulcerative colitis.